News FDA lends a hand to Novo, Lilly on illegal GLP-1 imports The FDA has set up a green list of overseas sources for GLP-1 ingredients to try to block imports of illegitimate and potentially unsafe materials.
News Ametris starts obesity digital endpoint project with pharma Ametris launches a collaboration with pharma companies that aims to show how digital endpoints can be used in obesity trials.
News ESC: Real-world study gives Wegovy edge over Lilly rival Novo Nordisk has latched onto a real-world study that found its weight-loss drug Wegovy works better than Eli Lilly's fast-growing rival Zepbound.
News Lilly pauses Mounjaro orders in UK ahead of price hike Lilly has paused shipments of weight loss therapy Mounjaro to the UK to prevent stockpiling ahead of a price rise, but patients report shortages.
News ESC: Study says GLP-1s treat heart failure AND cut emissions Add a beneficial impact on climate change to the long list of benefits being attributed to GLP-1 agonist medicines.
News New NHS diabetes strategy could raise GLP-1 drug use New guidelines on NHS management of type 2 diabetes will introduce a more personalised approach that could see expanded access to drug treatments.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.